MedTrace Logo

Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients

NCT04818970 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-06-15

No results posted yet for this study

Summary

The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes.

Conditions

Interventions

DEVICE

Narrow Band ultraviolet B-Band Light

Daily doses of NB-UVB for 8 consecutive days.

DEVICE

non Narrow Band ultraviolet B-Band Light

Daily doses of non-NB-UVB for 8 consecutive days.

Sponsors & Collaborators

  • Louisiana State University Health Sciences Center in New Orleans

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • West Jefferson Medical Center

    collaborator UNKNOWN

  • Cytokind, Inc.

    lead INDUSTRY

Principal Investigators

  • Frank H Lau, MD · Louisiana State University Health Sciences Center in New Orleans

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2021-10-31
Completion
2021-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818970 on ClinicalTrials.gov